Abstract
Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.(1) developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction.